Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418856 | 1.00 | HRH4 (0.43) | HRH4BCL2A1ALDH1A1LMNAADRA2A | |
| SCHEMBL18901972 | 0.90 | HRH4 (0.41) | HRH4BCL2A1ALDH1A1LMNAADRA2A | |
| SCHEMBL2417605 | 0.85 | HRH4 (0.41) | HRH4BCL2A1ALDH1A1LMNAKIT | |
| SCHEMBL2421495 | 0.83 | CXCR3 (0.41) | HRH4BCL2A1CXCR3 | |
| SCHEMBL2422155 | 0.82 | HRH4 (0.55) | HRH4BCL2A1ALDH1A1LMNAKIT | |
| SCHEMBL2417945 | 0.82 | CXCR3 (0.41) | CXCR3 | |
| SCHEMBL2420637 | 0.82 | CXCR3 (0.40) | HRH4BCL2A1ALDH1A1LMNACXCR3 | |
| SCHEMBL899509 | 0.81 | USP28 (0.43) | — | |
| SCHEMBL907759 | 0.80 | HRH4 (0.45) | HRH4BCL2A1ALDH1A1LMNAKIT | |
| SCHEMBL907761 | 0.80 | HRH4 (0.45) | HRH4BCL2A1ALDH1A1LMNAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HRH4 13/4885BCL2A1 2099/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.